Terms: = Gastric cancer AND HOXD13, SPD, 3239, P35453, HOX4I AND Prognosis
10 results:
1. Soluble programmed cell death ligand 1 predicts prognosis for gastric cancer patients treated with nivolumab: Blood-based biomarker analysis for the DELIVER trial.
Kawakami H; Sunakawa Y; Inoue E; Matoba R; Noda K; Sato T; Suminaka C; Yamaki M; Sakamoto Y; Kawabata R; Ishiguro A; Akamaru Y; Kito Y; Yabusaki H; Matsuyama J; Takahashi M; Makiyama A; Hayashi H; Chamoto K; Honjo T; Nakagawa K; Ichikawa W; Fujii M
Eur J Cancer; 2023 May; 184():10-20. PubMed ID: 36889037
[TBL] [Abstract] [Full Text] [Related]
2. Unbalanced expression of sICOS and spd-1 correlates with tumor progression in gastric cancer.
Lima CAC; da Silva LM; Dos Santos RL; Silva JPA; Forones NM; Martins MR; Torres LC
J Surg Oncol; 2022 Jul; 126(1):144-149. PubMed ID: 35689579
[TBL] [Abstract] [Full Text] [Related]
3. Circulating PD-L1 is associated with T cell infiltration and predicts prognosis in patients with CRLM following hepatic resection.
Chen X; Du Z; Huang M; Wang D; Fong WP; Liang J; Fan L; Wang Y; Yang H; Chen Z; Hu M; Xu R; Li Y
Cancer Immunol Immunother; 2022 Mar; 71(3):661-674. PubMed ID: 34322779
[TBL] [Abstract] [Full Text] [Related]
4. Prognostic significance of soluble forms of immune checkpoint PD-1/PDL1 receptor and ligand in blood plasma of gastric cancer patients.
Kushlinskii NE; Gershtein ES; Chang VL; Korotkova EA; Alferov AA; Kontorshchikov MM; Sokolov NY; Karamysheva EI; Ognerubov NA; Stilidi IS
Klin Lab Diagn; 2021 Mar; 66(3):139-146. PubMed ID: 33793112
[TBL] [Abstract] [Full Text] [Related]
5. GALNT10 promotes the proliferation and metastatic ability of gastric cancer and reduces 5-fluorouracil sensitivity by activating hoxd13.
Xu G; Wu YL; Li N; Xu R; Zhang JB; Ming H; Zhang Y
Eur Rev Med Pharmacol Sci; 2020 Nov; 24(22):11610-11619. PubMed ID: 33275228
[TBL] [Abstract] [Full Text] [Related]
6. Clinicopathological Features, Treatment Strategy, and prognosis of Primary Non-Hodgkin's Lymphoma of the Duodenum: A SEER Database Analysis.
Zheng G; Wang Y; Zhao Y; Zheng Z
Can J Gastroenterol Hepatol; 2020; 2020():9327868. PubMed ID: 32399459
[TBL] [Abstract] [Full Text] [Related]
7. Soluble PD-L1 Expression in Circulation as a Predictive Marker for Recurrence and prognosis in gastric cancer: Direct Comparison of the Clinical Burden Between Tissue and Serum PD-L1 Expression.
Shigemori T; Toiyama Y; Okugawa Y; Yamamoto A; Yin C; Narumi A; Ichikawa T; Ide S; Shimura T; Fujikawa H; Yasuda H; Hiro J; Yoshiyama S; Ohi M; Araki T; Kusunoki M
Ann Surg Oncol; 2019 Mar; 26(3):876-883. PubMed ID: 30565045
[TBL] [Abstract] [Full Text] [Related]
8. Pathological Significance and Prognostic Value of Surfactant Protein D in cancer.
Mangogna A; Belmonte B; Agostinis C; Ricci G; Gulino A; Ferrara I; Zanconati F; Tripodo C; Romano F; Kishore U; Bulla R
Front Immunol; 2018; 9():1748. PubMed ID: 30127783
[TBL] [Abstract] [Full Text] [Related]
9. Microsatellite Instability and Programmed Cell Death-Ligand 1 Expression in Stage II/III gastric cancer: Post Hoc Analysis of the CLASSIC Randomized Controlled study.
Choi YY; Kim H; Shin SJ; Kim HY; Lee J; Yang HK; Kim WH; Kim YW; Kook MC; Park YK; Kim HH; Lee HS; Lee KH; Gu MJ; Choi SH; Hong S; Kim JW; Hyung WJ; Noh SH; Cheong JH
Ann Surg; 2019 Aug; 270(2):309-316. PubMed ID: 29727332
[TBL] [Abstract] [Full Text] [Related]
10. HOX D13 expression across 79 tumor tissue types.
Cantile M; Franco R; Tschan A; Baumhoer D; Zlobec I; Schiavo G; Forte I; Bihl M; Liguori G; Botti G; Tornillo L; Karamitopoulou-Diamantis E; Terracciano L; Cillo C
Int J Cancer; 2009 Oct; 125(7):1532-41. PubMed ID: 19488988
[TBL] [Abstract] [Full Text] [Related]
